Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Trumps Drug Pricing Plan: The Headlines Are The Goal - But Also A Threat

Michael McCaughan 16 Jun 2022

The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.

Global Oncology Opportunities & Trends 2025: Key Markets, Indications and Product

13 May 2022

Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar!

Care Needed With Plain Language Summaries Of EU Study Results

Vibha Sharma 18 Jan 2022

The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.

A Deep Dive Into The Game-Changing Drugs For Skin Diseases

Scrip Team 17 Jan 2022

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

Alaric DeArment 05 Jan 2022

RandDsign_PanchenkoVladimir_507673309_1200x675

The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.

Generics Bulletin

Bio-Thera’s Bevacizumab US Action Date Passes Without Approval

01 Dec 2021

GB2112_27_November_2021_Calendar_2GY47JX_1200

Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.

Scrip

BI And Lilly Eye Acute Heart Failure Opportunity For Jardiance

16 Nov 2021

Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.

AstraZeneca Signs First COVID-19 Vaccine For-Profit Deals

Andrew McConaghie 12 Nov 2021

AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.

Comirnaty Gives Booster Shot To Pfizer Q3 Sales

Alaric DeArment 02 Nov 2021

Pfizer-BioNTechvaccineinglovedhand-1230011145

The company increased its guidance for sales of the COVID-19 vaccine again, to $36bn, though many other products’ sales were close to or below analyst expectations.

NIH Office Of Dietary Supplements Keeps Tabs On What DSHEA Wrought For US Consumers

Malcolm Spicer 31 Oct 2021

While working to improve the quality of VMS products available in the US and to provide information on the products to consumers, the ODS doesn’t have authority to impose change on the industry or in the marketplace.

Scrip

Sofinnova Raises €472m To Build Europe’s Biggest Early-Stage Investment Fund

By Andrew McConaghie 19 Oct 2021

The VC firm is making the most of a surge of capital from new and established investors who believe in the promise of European biopharma start-ups.

CureVac Pulls Covid Vaccine From European Review Process

12 Oct 2021

The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.

IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms

05 Oct 2021

With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.

Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook

01 Oct 2021

Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.

EU’s Health Emergency Response Plans Must Address Existing Flaws

17 Sep 2021

GB2109_EU_Flag_COVID_Coronavirus_2BD8JRX_1200

The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.